Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
In OurHealth Study, Researchers Seek Genetic Underpinnings of Cardiovascular Disease in South Asians
Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, ...
The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...
Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...
Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback